The confidential S-4 submission is a procedural step with no new deal terms. The next catalyst is the public filing of the S-4, which will reveal redemption estimates and financial projections. Monitor for shareholder vote timing and any material redemption activity.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $10.03entry
- T+1 · 13d ago +0.10%α −1.55% · $10.04
- T+5 · 7d ago +0.10%α +0.69% · $10.04
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
TCGX Acquisition Corp. and TriGemX Bio announced the confidential submission of a draft S-4 registration statement to the SEC, a procedural milestone toward completing their previously announced business combination. The deal is expected to close in Q1 2027, subject to shareholder approval, SEC effectiveness, and Nasdaq listing. No new material terms or changes to the deal structure were disclosed.
Key Financial Metrics
Key Facts
- TriGemX Bio and TCGX Acquisition Corp. confidentially submitted a draft registration statement on Form S-4 to the SEC on November 2, 2026.
- The business combination is expected to close in Q1 2027, subject to TCGX shareholder approval, SEC effectiveness, Nasdaq listing, and other customary conditions.
- The combined company will be named TriGemX Bio, Inc. and trade on Nasdaq under the ticker TGEM.
- Elismetrep, TriGemX Bio's migraine drug candidate, is in Phase 3 trials with first results expected in mid-2027.
- A $160 million PIPE financing at $10.00 per share backs the transaction, as previously disclosed.
- The deal values TriGemX at a pre-money equity value of $361 million (approximately $600 million total).
Financial Impact
No new financial figures disclosed; deal terms unchanged from prior announcement: $361 million pre-money equity value, $160 million PIPE at $10.00/share.
Risk Factors
- Risk of shareholder redemptions exceeding trust levels, which could reduce cash available to the combined company.
- Risk of SEC review delays or comments on the S-4, potentially pushing closing beyond Q1 2027.
- Risk that elismetrep Phase 3 data (mid-2027) may not support approval, but this is post-close risk.
- General SPAC market headwinds and regulatory scrutiny could affect deal completion.
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-443618 |
| Document: 0001193125-26-443618-index-headers.html | 0001193125-26-443618 |
| Document: 0001193125-26-443618-index.html | 0001193125-26-443618 |
| Document: 0001193125-26-443618.txt | 0001193125-26-443618 |
Track record
9 reports on TCGX
3 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +1.20% at T+5 after the Oct 19, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $10.00 Now $10.00 0.00% settles Nov 24
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $10.00 Now $10.00 0.00% settles Nov 24
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $10.01 Now $10.00 −0.10% settles Nov 23
- Nov 9, 20267d ago 425 Neutral 2/10 Entry $10.05 to $10.00 Now $10.00 −0.50% ▼ −0.50% +1.20% vs SPY
- Nov 2, 202614d ago 425 Neutral 3/10 Viewing Entry $10.03 to $10.04 Now $10.00 −0.30% ▲ +0.10% +0.69% vs SPY
- Oct 19, 202628d ago 425 Neutral 4/10 Entry $10.01 to $10.12 Now $10.00 −0.10% ▲ +1.10% +1.07% vs SPY
- Oct 19, 202628d ago 425 Bullish 6/10 Entry $10.01 to $10.12 Now $10.00 −0.10% ▲ +1.10% +1.07% vs SPY
- Oct 19, 202628d ago 425 Bullish 7/10 Entry $10.02 to $10.14 Now $10.00 −0.20% ▲ +1.20% +1.34% vs SPY
- Oct 19, 202628d ago 8-K Bullish 7/10 Entry $10.02 to $10.14 Now $10.00 −0.20% ▲ +1.20% +1.34% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers